Principal Financial Group Inc. Has $1.78 Million Position in RxSight, Inc. (NASDAQ:RXST)

Principal Financial Group Inc. lifted its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 0.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 36,046 shares of the company’s stock after buying an additional 240 shares during the quarter. Principal Financial Group Inc. owned about 0.10% of RxSight worth $1,782,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. CWM LLC lifted its position in RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the period. Quest Partners LLC acquired a new stake in RxSight during the 2nd quarter worth approximately $41,000. Amalgamated Bank boosted its stake in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in RxSight in the 2nd quarter valued at $156,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Oppenheimer dropped their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Finally, Stifel Nicolaus reduced their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight has a consensus rating of “Buy” and an average price target of $61.63.

RxSight Trading Down 0.5 %

NASDAQ RXST opened at $44.83 on Friday. The firm’s 50 day simple moving average is $49.39 and its 200 day simple moving average is $52.80. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -54.01 and a beta of 1.19. RxSight, Inc. has a 1 year low of $28.54 and a 1 year high of $66.54.

Insiders Place Their Bets

In other RxSight news, Director Jesse Anderson Corley bought 11,111 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the transaction, the director now directly owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Ilya Goldshleger sold 4,875 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $46.00, for a total value of $224,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $1,943,316. The trade was a 10.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 52,720 shares of company stock worth $2,603,950 over the last three months. Insiders own 9.36% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.